Page last updated: 2024-08-21

eriodictyol and Astrocytoma, Grade IV

eriodictyol has been researched along with Astrocytoma, Grade IV in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Du, Q; Li, L; Li, W; Liu, Q; Liu, S; Lv, F; Xi, X	1

Other Studies

1 other study(ies) available for eriodictyol and Astrocytoma, Grade IV

Article	Year
Eriodictyol inhibits glioblastoma migration and invasion by reversing EMT via downregulation of the P38 MAPK/GSK-3β/ZEB1 pathway. European journal of pharmacology, 2021, Jun-05, Volume: 900 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Down-Regulation; Epithelial-Mesenchymal Transition; Flavanones; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Molecular Docking Simulation; Neoplasm Invasiveness; Wound Healing; Zinc Finger E-box-Binding Homeobox 1	2021

Article

Year

Eriodictyol inhibits glioblastoma migration and invasion by reversing EMT via downregulation of the P38 MAPK/GSK-3β/ZEB1 pathway.

European journal of pharmacology, 2021, Jun-05, Volume: 900

Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Down-Regulation; Epithelial-Mesenchymal Transition; Flavanones; Glioblastoma; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Molecular Docking Simulation; Neoplasm Invasiveness; Wound Healing; Zinc Finger E-box-Binding Homeobox 1

2021